Clinical Trials Browser

pamiparib × Clear all

NCT04614909 2026-05-14

Study of Pamiparib in Newly Diagnosed and rGBM

Phase EARLY_PHASE1 Completed

Glioblastoma

NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT04164199 2026-05-08

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Active not recruiting

Advanced Malignancies

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03749187 2026-03-13

PNOC017

Phase 1 Active not recruiting

Glioblastoma, Glioma

NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Completed

Ovarian Neoplasms

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

Ovarian Neoplasms

NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Completed

116 enrolled 31 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT03333915 2025-02-04

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Phase 1/2 Completed

128 enrolled 36 charts

Triple Negative Breast Neoplasms

NCT03914742 2025-01-14

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Phase 1/2 Completed

67 enrolled 18 charts

Glioblastoma

NCT02361723 2024-12-27

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase 1 Completed

Other solid neoplasm

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

139 enrolled 36 charts

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT03427814 2024-10-26

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Phase 2 Completed

136 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

NCT03575065 2024-10-26

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase 2 Completed

88 enrolled 17 charts

HER2-negative Breast Cancer

NCT03994211 2024-10-26

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1 Completed

25 enrolled 33 charts

Other solid neoplasm

Solid Tumor

NCT06387056 2024-04-26

SEGNO

Phase 2 Recruiting

Locally Advanced Prostate Cancer

NCT05573373 2024-01-31

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05489926 2024-01-26

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Phase 2 Unknown

Carcinoma, Ovarian Epithelial

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Neoplasms

NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Phase 2 Withdrawn

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

NCT04985721 2023-03-15

IMPARP-HRD

Phase 2 Unknown

Neoplasms

NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Phase 2 Unknown

Neoadjuvant Therapy

NCT05669768 2023-01-03

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

Phase 2 Unknown

Ovarian Neoplasms

NCT05483543 2022-08-02

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Phase 2 Unknown

Limited Stage Small Cell Lung Cancer

NCT04796454 2022-06-01

PAMICC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT05327621 2022-04-14

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Phase 2 Unknown

Metastatic Castration-resistant Prostate Cancer

NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase 1 Completed

229 enrolled 46 charts

Other solid neoplasm

Solid Tumors

NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Phase 2 Terminated

13 enrolled 11 charts

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Neoplasms

NCT03933761 2021-08-10

PRECISE

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms